These antibodies are gaining attention as novel therapeutic agents in cancers where chronic CXCL10 expression contributes to immune evasion, tumor progression and metastasis.37,72 In many tumors, elevated levels of CXCL10 lead to the recruitment of immunosuppressive cells such as regulatory Tregs, MDSCs and M2-polarized macrophages, which collectively dampen antitumor immunity. Here, CXCL10 is linked to neoplasm.